Dermata Therapeutics, Inc. (DRMA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DRMA
- Company Dermata Therapeutics, Inc.
- Price $1.93
- Changes Percentage 50.78
- Change 0.65
- Day Low $1.28
- Day High $2.29
- Year High $23.7
- Year Low $1.29
- Market Cap $1,315,405
- Price Avg 50 EMA (D) $2.23
- Price Avg 200 EMA (D) $4.87
- Exchange NASDAQ
- Volume 35,703,439
- Average Volume 1,537,726
- Open $1.28
- Previous Close $1.28
- EPS 15.24
- PE 0.13
- Earnings Announcement 2026-03-25 12:00:00
- Shares Outstanding $681,557
Company brief: DERMATA THERAPEUTICS, INC. (DRMA )
- Healthcare
- Biotechnology
- Mr. Gerald T. Proehl
- https://www.dermatarx.com
- US
- N/A
- 08-13-2021
- US2498453065
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.